Home › Rating Schedule › Hemic and Lymphatic Systems
Diagnostic Code 7702: Agranulocytosis, acquired
Hemic and Lymphatic Systems · 38 CFR §4.117 · All codes in this system
| Evaluation criteria | Rating |
|---|---|
| Requiring bone marrow transplant; or infections recurring, on average, at least once every six weeks per 12-month period | 100% |
| Requiring intermittent myeloid growth factors (granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF) or continuous immunosuppressive therapy such as cyclosporine to maintain absolute neutrophil count (ANC) greater than 500/microliter (µl) but less than 1000/µl; or infections recurring, on average, at least once every three months per 12-month period | 60% |
| Requiring intermittent myeloid growth factors to maintain ANC greater than 1000/µl; or infections recurring, on average, at least once per 12-month period but less than once every three months per 12-month period | 30% |
| Requiring continuous medication (e.g., antibiotics) for control; or requiring intermittent use of a myeloid growth factor to maintain ANC greater than or equal to 1500/µl | 10% |
| Note: A 100 percent evaluation for bone marrow transplant shall be assigned as of the date of hospital admission and shall continue with a mandatory VA examination six months following hospital discharge. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of § 3.105(e) of this chapter | |
Use this rating
Open the combined ratings calculator with this percentage already entered, then add your other rated conditions:
100% in the calculator 60% in the calculator 30% in the calculator 10% in the calculator
Source: eCFR Title 38, 38 CFR §4.117, current as of 2026-11-05. Criteria text is the regulatory text, reproduced verbatim for reference; it is not legal advice.